Elanco Animal Health (ELAN) Expected to Announce Quarterly Earnings on Wednesday

Elanco Animal Health (NYSE:ELAN) is projected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Elanco Animal Health to post earnings of $0.28 per share and revenue of $1.3125 billion for the quarter. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the prior year, the company posted $0.37 EPS. The business’s revenue was up 14.9% on a year-over-year basis. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded up $0.19 during trading on Wednesday, hitting $25.71. 641,704 shares of the company’s stock traded hands, compared to its average volume of 5,258,759. The company has a market cap of $12.84 billion, a PE ratio of -51.26, a PEG ratio of 1.66 and a beta of 1.68. The firm’s fifty day moving average price is $24.24 and its 200 day moving average price is $24.01. Elanco Animal Health has a twelve month low of $13.39 and a twelve month high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Citigroup upped their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $28.73.

Insider Activity

In other Elanco Animal Health news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by company insiders.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC grew its holdings in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares during the period. Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health in the fourth quarter valued at about $41,000. Geneos Wealth Management Inc. increased its holdings in Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after purchasing an additional 2,080 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after buying an additional 1,332 shares during the period. Finally, UMB Bank n.a. lifted its stake in Elanco Animal Health by 31.9% in the fourth quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after buying an additional 1,358 shares during the period. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.